Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat phase 3 placebo-controlled study in children with sickle cell disease
2025-524464-38-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Etavopivat with Matching placebo (2 arms). Primary endpoint: Annualised rate of adjudicated vaso-occlusive crisis events with a medical contact. Planned start Sep 2026; status: authorised.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2025-524464-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524464-38-00.